Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial

201976 citationsJournal Article

Authors

Jian-Ming Xu · 307th Hospital of Chinese People’s Liberation Army

Jie Li · Ministry of Education

Chunmei Bai · Chinese Academy of Medical Sciences & Peking Union Medical College

Nong Xu · First Affiliated Hospital Zhejiang University

Zhiwei Zhou · Sun Yat-sen University

Zhiping Li · Sichuan University

Caicun Zhou

Abstract

Surufatinib showed encouraging antitumor activity and manageable toxicities in patients with advanced NETs. Two ongoing phase III studies, validating the efficacy of surufatinib in patients with NETs, will contribute to the clinical evidence.

Topics & Keywords

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 12, pp. 3486-3494

DOI: 10.1158/1078-0432.ccr-18-2994

Field-Weighted Citation Impact: 7.48